• Something wrong with this record ?

Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation

B. Tessier-Cloutier, FKF. Kommoss, DL. Kolin, K. Němejcová, D. Smith, J. Pors, CJR. Stewart, WG. McCluggage, WD. Foulkes, A. von Deimling, M. Köbel, CH. Lee

. 2024 ; 37 (1) : 100374. [pub] 20231103

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24007811

Dedifferentiated and undifferentiated ovarian carcinomas (DDOC/UDOC) are rare neoplasms defined by the presence of an undifferentiated carcinoma. In this study, we detailed the clinical, pathological, immunohistochemical, and molecular features of a series of DDOC/UDOC. We collected a multi-institutional cohort of 23 DDOC/UDOC and performed immunohistochemistry for core switch/sucrose nonfermentable (SWI/SNF) complex proteins (ARID1A, ARID1B, SMARCA4, and SMARCB1), mismatch repair (MMR) proteins, and p53. Array-based genome-wide DNA methylation and copy number variation analyses were performed on a subset of cases with comparison made to a previously reported cohort of undifferentiated endometrial carcinoma (UDEC), small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), and tubo-ovarian high-grade serous carcinoma (HGSC). The age of all 23 patients with DDOC/UDOC ranged between 22 and 71 years (with an average age of 50 years), and a majority of them presented with extraovarian disease (16/23). Clinical follow-up was available for 19 patients. Except for 2 patients, the remaining 17 patients died from disease, with rapid disease progression resulting in mortality within a year in stage II-IV settings (median disease-specific survival of 3 months). Eighteen of 22 cases with interpretable immunohistochemistry results showed loss of expression of core SWI/SNF protein(s) that are expected to result in SWI/SNF complex inactivation as 10 exhibited coloss of ARID1A and ARID1B, 7 loss of SMARCA4, and 1 loss of SMARCB1. Six of 23 cases were MMR-deficient. Two of 20 cases exhibited mutation-type p53 immunoreactivity. Methylation profiles showed coclustering of DDOC/UDOC with UDEC, which collectively were distinct from SCCOHT and HGSC. However, DDOC/UDOC showed an intermediate degree of copy number variation, which was slightly greater, compared with SCCOHT but much less compared with HGSC. Overall, DDOC/UDOC, like its endometrial counterpart, is highly aggressive and is characterized by frequent inactivation of core SWI/SNF complex proteins and MMR deficiency. Its molecular profile overlaps with UDEC while being distinct from SCCOHT and HGSC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007811
003      
CZ-PrNML
005      
20240423160305.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.modpat.2023.100374 $2 doi
035    __
$a (PubMed)37925057
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tessier-Cloutier, Basile $u Department of Pathology and Laboratory Medicine, McGill University Health Centre, Montreal, Quebec, Canada
245    10
$a Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation / $c B. Tessier-Cloutier, FKF. Kommoss, DL. Kolin, K. Němejcová, D. Smith, J. Pors, CJR. Stewart, WG. McCluggage, WD. Foulkes, A. von Deimling, M. Köbel, CH. Lee
520    9_
$a Dedifferentiated and undifferentiated ovarian carcinomas (DDOC/UDOC) are rare neoplasms defined by the presence of an undifferentiated carcinoma. In this study, we detailed the clinical, pathological, immunohistochemical, and molecular features of a series of DDOC/UDOC. We collected a multi-institutional cohort of 23 DDOC/UDOC and performed immunohistochemistry for core switch/sucrose nonfermentable (SWI/SNF) complex proteins (ARID1A, ARID1B, SMARCA4, and SMARCB1), mismatch repair (MMR) proteins, and p53. Array-based genome-wide DNA methylation and copy number variation analyses were performed on a subset of cases with comparison made to a previously reported cohort of undifferentiated endometrial carcinoma (UDEC), small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), and tubo-ovarian high-grade serous carcinoma (HGSC). The age of all 23 patients with DDOC/UDOC ranged between 22 and 71 years (with an average age of 50 years), and a majority of them presented with extraovarian disease (16/23). Clinical follow-up was available for 19 patients. Except for 2 patients, the remaining 17 patients died from disease, with rapid disease progression resulting in mortality within a year in stage II-IV settings (median disease-specific survival of 3 months). Eighteen of 22 cases with interpretable immunohistochemistry results showed loss of expression of core SWI/SNF protein(s) that are expected to result in SWI/SNF complex inactivation as 10 exhibited coloss of ARID1A and ARID1B, 7 loss of SMARCA4, and 1 loss of SMARCB1. Six of 23 cases were MMR-deficient. Two of 20 cases exhibited mutation-type p53 immunoreactivity. Methylation profiles showed coclustering of DDOC/UDOC with UDEC, which collectively were distinct from SCCOHT and HGSC. However, DDOC/UDOC showed an intermediate degree of copy number variation, which was slightly greater, compared with SCCOHT but much less compared with HGSC. Overall, DDOC/UDOC, like its endometrial counterpart, is highly aggressive and is characterized by frequent inactivation of core SWI/SNF complex proteins and MMR deficiency. Its molecular profile overlaps with UDEC while being distinct from SCCOHT and HGSC.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mladý dospělý $7 D055815
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
650    _2
$a variabilita počtu kopií segmentů DNA $7 D056915
650    12
$a nádory vaječníků $x genetika $x patologie $7 D010051
650    12
$a karcinom $x patologie $7 D002277
650    _2
$a epiteliální ovariální karcinom $7 D000077216
650    12
$a nádory endometria $x patologie $7 D016889
650    12
$a malobuněčný karcinom $7 D018288
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a DNA-helikasy $x genetika $x metabolismus $7 D004265
650    _2
$a jaderné proteiny $x genetika $7 D009687
650    _2
$a transkripční faktory $x genetika $x metabolismus $7 D014157
650    12
$a nádory mozku $7 D001932
650    12
$a dědičné nádorové syndromy $7 D009386
650    12
$a kolorektální nádory $7 D015179
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kommoss, Felix K F $u Institute of Pathology, University of Heidelberg, Heidelberg, Germany
700    1_
$a Kolin, David L $u Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts
700    1_
$a Němejcová, Kristýna $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Smith, DuPreez $u Department of Obstetrics and Gynecology, University of Alberta, Edmonton, Alberta, Canada
700    1_
$a Pors, Jennifer $u Department of Pathology and Laboratory Medicine, BC Cancer, Vancouver, British Columbia, Canada
700    1_
$a Stewart, Colin J R $u Department of Pathology, King Edward Memorial Hospital, Perth, Australia
700    1_
$a McCluggage, W Glenn $u Department of Pathology, Belfast Health and Social Care Trust, Belfast, United Kingdom
700    1_
$a Foulkes, William D $u Departments of Human Genetics, McGill University, Montreal, Quebec, Canada
700    1_
$a von Deimling, Andreas $u Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany; CCU Neuropathology, German Cancer Center (DKFZ), Heidelberg, Germany
700    1_
$a Köbel, Martin $u Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
700    1_
$a Lee, Cheng-Han $u Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada. Electronic address: chlee2@ualberta.ca
773    0_
$w MED00003380 $t Modern pathology $x 1530-0285 $g Roč. 37, č. 1 (2024), s. 100374
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37925057 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160302 $b ABA008
999    __
$a ok $b bmc $g 2081669 $s 1217578
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 37 $c 1 $d 100374 $e 20231103 $i 1530-0285 $m Modern pathology $n Mod Pathol $x MED00003380
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options